Search

223 Result(s)
Sort by

Facing lung cancer

Facing lung cancer

Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Living With Cancer

Living With Cancer

Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Four Pillars Cancer Immunology

Four Pillars Cancer Immunology

Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Weight Loss from Cancer Treatment

Weight Loss from Cancer Treatment

Discover advice on how to put weight back on following cancer treatment from Taking Cancer On Through Flavour
Taking cancer on together

Taking cancer on together

Through their work, our colleagues from around the world hope to empower patients to Take Cancer On.
Taking Cancer on at Diagnosis

Taking Cancer on at Diagnosis

We spoke to Markus, Brigitte and Dr Hochmair who shared their advice for people starting their own cancer journeys.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Dedifferentiated liposarcoma (DDLPS)

Dedifferentiated liposarcoma (DDLPS)

An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.